Media stories about RadNet (NASDAQ:RDNT) have been trending somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. RadNet earned a news impact score of 0.19 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 45.8936024777637 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news articles that may have impacted Accern Sentiment’s rankings:
- RadNet, Inc. (RDNT) Director Sells $274,500.00 in Stock (americanbankingnews.com)
- RadNet Inc. (RDNT) Insider Sells $107,200.00 in Stock (americanbankingnews.com)
- RadNet, NantWorks and Verity Health System Announce Strategic Relationships Related to Breast Cancer and Integrated Care Models, Clinical Trials, High Speed Fiber Optics and Artificial Intelligence (finance.yahoo.com)
RadNet (NASDAQ RDNT) traded up 2.055% during mid-day trading on Tuesday, hitting $11.175. 182,581 shares of the stock were exchanged. RadNet has a 52 week low of $5.25 and a 52 week high of $11.20. The company’s 50-day moving average price is $8.84 and its 200 day moving average price is $7.20. The firm has a market capitalization of $528.20 million, a price-to-earnings ratio of 58.816 and a beta of 0.92.
RadNet (NASDAQ:RDNT) last released its quarterly earnings results on Tuesday, August 8th. The medical research company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.07. RadNet had a net margin of 1.04% and a return on equity of 19.98%. The firm had revenue of $230.00 million during the quarter, compared to analysts’ expectations of $230.32 million. During the same period in the previous year, the company earned $0.09 EPS. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. Equities research analysts expect that RadNet will post $0.29 EPS for the current year.
RDNT has been the subject of several analyst reports. TheStreet upgraded shares of RadNet from a “c” rating to a “b-” rating in a research report on Thursday, August 24th. Jefferies Group LLC upgraded shares of RadNet from a “hold” rating to a “buy” rating and upped their price target for the company from $7.00 to $12.00 in a research report on Tuesday, August 22nd. Zacks Investment Research upgraded shares of RadNet from a “sell” rating to a “hold” rating in a research report on Wednesday, May 17th. Finally, BidaskClub upgraded shares of RadNet from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 24th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $9.63.
In related news, insider Jeffrey L. Linden sold 10,000 shares of RadNet stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $10.72, for a total transaction of $107,200.00. Following the completion of the transaction, the insider now directly owns 950,193 shares of the company’s stock, valued at approximately $10,186,068.96. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director David L. Swartz sold 25,000 shares of RadNet stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $10.98, for a total transaction of $274,500.00. Following the transaction, the director now directly owns 274,108 shares of the company’s stock, valued at $3,009,705.84. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 91,782 shares of company stock valued at $885,603. 9.36% of the stock is owned by corporate insiders.
RadNet Company Profile
RadNet, Inc is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island.
Receive News & Ratings for RadNet Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet Inc. and related companies with MarketBeat.com's FREE daily email newsletter.